Reid Huber is a partner at Third Rock Ventures, joining in 2018 to focus on the formation, development and strategy of the firm’s portfolio companies. He has over 20 years of experience in biotech strategy and operations, ranging from early drug discovery to commercial execution and currently serves as a board member at Bellicum Pharmaceuticals, Inc. and The Andrew McDonough B+ Foundation.
Before joining Third Rock, he spent 16 years at Incyte, where he was a member of the founding scientific team. During his time at Incyte, he served in multiple senior leadership roles including senior vice president, discovery biology, executive vice president and chief scientific officer. He worked across many therapeutic areas, gaining extensive knowledge of pharmaceutical research and clinical development. Prior to that, Reid held positions of increasing responsibility at DuPont Pharmaceuticals and Bristol-Myers Squibb.
Reid earned his doctorate in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes of Health. He obtained his Bachelor of Science in molecular genetics and biochemistry from Murray State University.